FDA Warns of Increased Heart-Related Issues From Pfizer’s Xeljanz

The U.S. health regulator has added a new “boxed warning” to Pfizer Inc’s arthritis drug, Xeljanz, and revised its prescription, citing increased risk of major cardiac-related problems in some patients, the drugmaker said on Friday. Read More